Barry Baxter

Barry L. Baxter is a procurement professional responsible for managing complex acquisitions within the federal health and life sciences sector, focusing on high-precision medical technologies and diagnostic services. He plays a critical role in executing contract actions aligned with federal acquisition regulations, ensuring compliance with statutory requirements for competition, technical evaluation, and socioeconomic goals. His portfolio primarily encompasses medical instrumentation, in-vitro diagnostic substances, clinical laboratory services, and specialized professional technical support, requiring deep domain knowledge in regulatory frameworks such as FDA clearance pathways and CLIA compliance. While specific contractor names are not available, Baxter consistently engages with a diverse pool of vendors, including manufacturers of surgical and medical devices, clinical testing laboratories, and niche scientific service providers. His contracting patterns reflect a preference for competitive sealed bidding and negotiated acquisitions under FAR Part 15, with a strong emphasis on technical merit and performance-based outcomes. He maintains collaborative relationships with both large-capability contractors and small businesses, ensuring robust market engagement and innovation infusion. Baxter demonstrates a pronounced commitment to small business participation, with over 25% of his awards directed toward small business set-asides under FAR 19.5, including a notable 3.9% allocation to service-disabled veteran-owned small businesses. His procurement strategy prioritizes socioeconomic objectives without compromising technical rigor, consistently balancing full and open competition with targeted set-asides to foster equitable market access. His core procurement focus lies in NAICS 811219 (Medical and Diagnostic Laboratories), 339112 (Surgical and Medical Instrument Manufacturing), and 325413 (In-Vitro Diagnostic Substance Manufacturing), reflecting deep expertise in laboratory diagnostics, precision medical devices, and life science supply chains. He routinely procures FDA-regulated products and services requiring validation, quality control, and traceability standards, positioning him as a key steward of clinical-grade procurement within the federal health infrastructure.